Krystal Biotech Sees FY26 Non-GAAP R&D And SG&A Expense $155M-$165M
Share
Why It Matters
Krystal Biotech plans to spend between 155 and 165 million dollars next year. That money goes to research, development, and running the business, which shows they are growing their company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.